dostęp otwarty
Avelumab use in Merkel cell carcinoma treatment
, 1, 1, 1, 1
Afiliacje- Department of Soft Tissue/Bone Sarcoma and Melanoma, Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland
dostęp otwarty
Streszczenie
Avelumab is a programmed death-ligand 1 (PD-L1) blocking human IgG1 lambda monoclonal antibody. It was the first immunotherapy to be approved for the treatment of MCC. In March 2017, the FDA granted accelerated approval to avelumab for the treatment of adults and pediatric patients 12 years and older with metastatic Merkel cell carcinoma (MCC) –irrespective of prior therapy. In July 2017, the European Medicines Agency (EMA) recommended the approval of avelumab as a monotherapy for the treatment of adult patients with metastatic Merkel cell carcinoma (mMCC). Approvals were based on the efficacy and safety demonstrated in JAVELIN Merkel 200 (NCT02155647), a multi-center, open-label, single-arm, phase II clinical trial [1]. Part A of the study consisted of patients treated in the second line with metastatic, chemotherapy-refractory MCC. Part B consisted of systemic treatment-naive patients who received avelumab as a first-line treatment for metastatic or distally recurrent MCC. In the first line the ORR is 39.7%. Durable responses lasting at least 6 months were observed and the majority of responses are observed early with the median time to response of 6.1 week. PFS rate at 6 and 12 months are 41% and 31%, respectively. Median OS is 20.3 months. The OS rate at 1 year is 60%.
Streszczenie
Avelumab is a programmed death-ligand 1 (PD-L1) blocking human IgG1 lambda monoclonal antibody. It was the first immunotherapy to be approved for the treatment of MCC. In March 2017, the FDA granted accelerated approval to avelumab for the treatment of adults and pediatric patients 12 years and older with metastatic Merkel cell carcinoma (MCC) –irrespective of prior therapy. In July 2017, the European Medicines Agency (EMA) recommended the approval of avelumab as a monotherapy for the treatment of adult patients with metastatic Merkel cell carcinoma (mMCC). Approvals were based on the efficacy and safety demonstrated in JAVELIN Merkel 200 (NCT02155647), a multi-center, open-label, single-arm, phase II clinical trial [1]. Part A of the study consisted of patients treated in the second line with metastatic, chemotherapy-refractory MCC. Part B consisted of systemic treatment-naive patients who received avelumab as a first-line treatment for metastatic or distally recurrent MCC. In the first line the ORR is 39.7%. Durable responses lasting at least 6 months were observed and the majority of responses are observed early with the median time to response of 6.1 week. PFS rate at 6 and 12 months are 41% and 31%, respectively. Median OS is 20.3 months. The OS rate at 1 year is 60%.
Słowa kluczowe
Merkel cell carcinoma; avelumab; immunotherapy; skin
Informacje o artykuleTytuł
Avelumab use in Merkel cell carcinoma treatment
Czasopismo
Biuletyn Polskiego Towarzystwa Onkologicznego Nowotwory
Numer
Typ artykułu
Artykuł przeglądowy
Strony
421-427
Opublikowany online
2022-09-09
Wyświetlenia strony
3295
Wyświetlenia/pobrania artykułu
134
Rekord bibliograficzny
Biuletyn Polskiego Towarzystwa Onkologicznego Nowotwory 2022;7(6):421-427.
Słowa kluczowe
Merkel cell carcinoma
avelumab
immunotherapy
skin
Autorzy
Monika Dudzisz-Śledź
Martyna Zwierzchowska
Elżbieta Bylina
Piotr Rutkowski
Anna M. Czarnecka
Referencje (29)- Kaufman H, Russell J, Hamid O, et al. Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial. Lancet Oncol. 2016; 17(10): 1374–1385.
- Becker J, Stang A, DeCaprio J, et al. Merkel cell carcinoma. Nat Rev Dis Primers. 2017; 3(1).
- Paulson KG, Park SY, Vandeven NA, et al. Merkel cell carcinoma: Current US incidence and projected increases based on changing demographics . J Am Acad Dermatol. 2018; 78(3): 457–463.e2.
- Becker JC, Stang A, Hausen AZ, et al. Epidemiology, biology and therapy of Merkel cell carcinoma: conclusions from the EU project IMMOMEC. Cancer Immunol Immunother. 2018; 67(3): 341–351.
- Fitzgerald TL, Dennis S, Kachare SD, et al. Dramatic Increase in the Incidence and Mortality from Merkel Cell Carcinoma in the United States. Am Surg. 2015; 81(8): 802–806.
- Dudzisz-Śledź M, Zdzienicki M, Rutkowski P. Merkel cell carcinoma (MCC) – neuroendocrine skin cancer. Nowotwory. Journal of Oncology. 2019; 69(3-4): 111–116.
- Stachyra K, Dudzisz-Śledź M, Bylina E, et al. Merkel Cell Carcinoma from Molecular Pathology to Novel Therapies. Int J Mol Sci. 2021; 22(12).
- Feng H, Shuda M, Chang Y, et al. Clonal integration of a polyomavirus in human Merkel cell carcinoma. Science. 2008; 319(5866): 1096–1100.
- Heath M, Jaimes N, Lemos B, et al. Clinical characteristics of Merkel cell carcinoma at diagnosis in 195 patients: the AEIOU features. J Am Acad Dermatol. 2008; 58(3): 375–381.
- Dudzisz-Sledz M, Sobczuk P, Kozak K, et al. Treatment of Locally Advanced Merkel Cell Carcinoma-A Multi-Center Study. Cancers (Basel). 2022; 14(2).
- Lemos B, Storer B, Iyer J, et al. Pathologic nodal evaluation improves prognostic accuracy in Merkel cell carcinoma: Analysis of 5823 cases as the basis of the first consensus staging system. J Am Acad Dermatol. 2010; 63(5): 751–761.
- Schmults CDD, Park S, Blitzblau R, et al. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) Merkel Cell Carcinoma Version 1.2021 — February 18, 2021. National Comprehensive Cancer Network: Plymouth Meeting, PA, USA 2021.
- Becker JC. Merkel cell carcinoma. Ann Oncol. 2010; 21: vii81–vii85.
- Chandra S, Zheng Y, Pandya S, et al. Real-world outcomes among US Merkel cell carcinoma patients initiating immune checkpoint inhibitors or chemotherapy. Future Oncol. 2020; 16(31): 2521–2536.
- Iyer JG, Blom A, Doumani R, et al. Response rates and durability of chemotherapy among 62 patients with metastatic Merkel cell carcinoma. Cancer Med. 2016; 5(9): 2294–2301.
- Nghiem P, Bhatia S, Brohl A, et al. Two-year efficacy and safety update from JAVELIN Merkel 200 part A: A registrational study of avelumab in metastatic Merkel cell carcinoma progressed on chemotherapy. J Clin Oncol. 2018; 36(15_suppl): 9507–9507.
- D'Angelo S, Russell J, Bhatia S, et al. 18-month efficacy and safety update from JAVELIN Merkel 200 part A: A phase II study of avelumab in metastatic Merkel cell carcinoma progressed on chemotherapy. J Clin Oncol. 2018; 36(5_suppl): 192–192.
- Kaufman HL, Russell JS, Hamid O, et al. Updated efficacy of avelumab in patients with previously treated metastatic Merkel cell carcinoma after ≥1 year of follow-up: JAVELIN Merkel 200, a phase 2 clinical trial. J Immunother Cancer. 2018; 6(1): 7.
- D'Angelo SP, Bhatia S, Brohl AS, et al. Avelumab in patients with previously treated metastatic Merkel cell carcinoma: long-term data and biomarker analyses from the single-arm phase 2 JAVELIN Merkel 200 trial. J Immunother Cancer. 2020; 8(1).
- D'Angelo SP, Bhatia S, Brohl AS, et al. Avelumab in patients with previously treated metastatic Merkel cell carcinoma (JAVELIN Merkel 200): updated overall survival data after >5 years of follow-up. ESMO Open. 2021; 6(6): 100290.
- D'Angelo SP, Russell J, Lebbé C, et al. Efficacy and Safety of First-line Avelumab Treatment in Patients With Stage IV Metastatic Merkel Cell Carcinoma: A Preplanned Interim Analysis of a Clinical Trial. JAMA Oncol. 2018; 4(9): e180077.
- D'Angelo S, Russell J, Hassel J, et al. First-line (1L) avelumab treatment in patients (pts) with metastatic Merkel cell carcinoma (mMCC): Preliminary data from an ongoing study. J Clin Oncol. 2017; 35(15_suppl): 9530–9530.
- Bullement A, D'Angelo SP, Amin A, et al. Predicting overall survival in patients (pts) with treatment-naive metastatic Merkel cell carcinoma (mMCC) treated with avelumab . J Clin Oncol. 2018; 36(15_suppl): e21620–e21620.
- D'Angelo SP, Lebbé C, Mortier L, et al. First-line avelumab in a cohort of 116 patients with metastatic Merkel cell carcinoma (JAVELIN Merkel 200): primary and biomarker analyses of a phase II study. J Immunother Cancer. 2021; 9(7).
- Nghiem P, Bhatia S, Lipson E, et al. Durable Tumor Regression and Overall Survival in Patients With Advanced Merkel Cell Carcinoma Receiving Pembrolizumab as First-Line Therapy. J Clin Oncol. 2019; 37(9): 693–702.
- Correction: Efficacy and safety of avelumab treatment in patients with metastatic Merkel cell carcinoma: experience from a global expanded access program. J Immunother Cancer. 2020; 8(1).
- Ascierto PA, Orlova K, Grignani G, et al. Avelumab expanded access program in metastatic Merkel cell carcinoma: Efficacy and safety findings from patients in Europe and the Middle East. Int J Cancer. 2021; 149(11): 1926–1934.
- Tai P, Au J. Skin cancer management-updates on Merkel cell carcinoma. Ann Transl Med. 2018; 6(14): 282.
- Bhatia S, Brohl A, Brownell I, et al. ADAM trial: A multicenter, randomized, double-blinded, placebo-controlled, phase 3 trial of adjuvant avelumab (anti-PD-L1 antibody) in merkel cell carcinoma patients with clinically detected lymph node metastases; NCT03271372. J Clin Oncol. 2018; 36(15_suppl): TPS9605–TPS9605.
